One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Investor's Business Daily on MSN9m
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial ResultsNovo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback